What is the typical development timeline for a custom BiTE target engagement assay?

A: The development timeline is program-dependent and is influenced by the context of use, reagent availability, and the required level of GxP validation. A detailed timeline is established following initial project scoping.

Which biological matrices can you validate these assays for?

A: We routinely develop and validate assays for a range of matrices including plasma, serum, whole blood, peripheral blood mononuclear cells (PBMCs), and tissue homogenates. Matrix selection is guided by the program’s specific biological questions.

How do you ensure an assay distinguishes between the BiTE binding to its two distinct targets?

A: We employ multi-platform strategies. This can involve developing parallel assays for each arm of the BiTE or designing a single bridging assay that requires the simultaneous presence of both targets (e.g., the T-cell co-receptor and the tumor-associated antigen) for signal generation.

What GxP standards are applied to these custom assay development projects?

A: All bioanalytical method development and validation activities are conducted within our GxP framework, aligning with current FDA, EMA, and ICH guidelines. This ensures data integrity and regulatory acceptance for IND and other submissions.

Developing robust bioanalytical assays for Bi-specific T-cell Engagers (BiTEs) requires a specialized approach. Standard immunoassays are often insufficient to characterize the tripartite synapse formation (T-cell, BiTE, target cell) that defines the mechanism of action. A custom-developed, validated target engagement assay is necessary to accurately quantify pharmacodynamics, confirm the mechanism of action in vivo, and establish a clear PK/PD relationship to inform dose selection and de-risk clinical development.

Bi-specific T-cell Engagers function by physically linking a T-cell to a target cell, inducing T-cell activation and subsequent target cell lysis. A meaningful bioanalytical strategy provides evidence of target engagement at the cellular level, supplementing the quantification of free drug concentration in circulation.

Key bioanalytical questions for a BiTE program include:

• Is the BiTE simultaneously engaging both the T-cell and the target cell?

• What level of target engagement is required to induce T-cell activation and downstream signaling?

• Does the level of engagement correlate with biomarkers of efficacy or safety, such as cytokine release?

• How does receptor density on either cell type affect the dose-response relationship?

Answering these questions requires purpose-built assays designed to measure the formation of this complex biological structure.

Our approach to developing a target engagement assay is built on a foundation of deep biological understanding and rigorous analytical validation. We collaborate with sponsors to define the specific context of use for the assay, which dictates the required level of validation.

The development process considers several factors:

• Platform Selection: We leverage multiple platforms, including Meso Scale Discovery (MSD) for high-sensitivity bridging assays, flow cytometry for cellular engagement analysis on specific cell subsets, and ligand-binding assays (LBA) for quantitative PK measurements.

• Reagent Characterization: The performance of any assay is dependent on the quality of its reagents. We conduct extensive characterization and qualification of all reagents, including anti-idiotypic antibodies and recombinant target proteins, in coordination with specialized suppliers.

• Assay Format: We design formats to specifically measure the active, dual-bound BiTE. This may involve a bridging ELISA format or a cell-based assay that measures a functional outcome, such as cytokine production or induced cell death.

Watch the full-length video ‘DIVERSIFYING THE VALUE CHAIN’

While BiTEs and viral vectors are distinct modalities, insights from monitoring cellular immune responses in gene therapy can inform BiTE bioanalytical strategies. For instance, the development of tools to identify specific CD8+ T-cell epitopes (PMID: 19777488) underscores the value of having precise methods to monitor targeted cellular immunity. For a BiTE, this translates to developing assays that can specifically measure T-cell activation in the presence of the drug and target cell.

Understanding mechanisms of immune modulation, such as T-cell exhaustion (PMID: 23778424), is also directly relevant. Sustained engagement by a BiTE could potentially lead to T-cell exhaustion, limiting therapeutic efficacy. A comprehensive bioanalytical package includes assays for monitoring biomarkers of T-cell activation and exhaustion (e.g., PD-1, TIM-3) on relevant cell populations over time.

Franklin Biolabs provides the infrastructure and expertise to move your program forward with confidence. Our >100,000 sq ft facility is equipped for complex bioanalytical projects. We operate within a stringent GxP quality system, ensuring that the data generated is reliable and suitable for regulatory submissions. This rigorous approach to bioanalysis is a key component supporting an 18-24 month IND timeline.

Our focus on robust, reproducible data has contributed to a 100% successful IND rate for our clients’ programs since 2019. (The Franklin Biolabs brand launched in 2024, building upon this established operational history).